{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:18:41Z","timestamp":1784791121498,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00108-026-02131-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:22:55Z","timestamp":1780392175000},"page":"918-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surrogatmarker in der chronischen Nierenkrankheit","Surrogate markers in chronic kidney disease"],"prefix":"10.1007","volume":"67","author":[{"given":"Jan","family":"Galle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kintscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Marx-Sch\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2131_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn\u00a0BR, Manns\u00a0BJ, Lloyd\u00a0A et\u00a0al (2010) Relation between kidney function, proteinuria, and adverse outcomes. Jama 303:423\u2013429","journal-title":"Jama"},{"key":"2131_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita\u00a0K, Van Der Velde\u00a0M, Astor\u00a0BC et\u00a0al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073\u20132081","journal-title":"Lancet"},{"key":"2131_CR3","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH De Boer","year":"2022","unstructured":"De Boer\u00a0IH, Khunti\u00a0K, Sadusky\u00a0T et\u00a0al (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45:3075\u20133090","journal-title":"Diabetes Care"},{"key":"2131_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak\u00a0MG, Tummalapalli\u00a0SL, Boulware\u00a0LE et\u00a0al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 99:34\u201347","journal-title":"Kidney Int"},{"key":"2131_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey\u00a0AS, Gansevoort\u00a0RT, Coresh\u00a0J et\u00a0al (2020) Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 75:84\u2013104","journal-title":"Am J Kidney Dis"},{"key":"2131_CR6","unstructured":"Deutsche Gesellschaft F\u00fcr Nephrologie (2025) Au\u00dferordentliche Stellungnahme der Deutschen Gesellschaft f\u00fcr Nephrologie (DGfN) e.\u202fV. zur Akzeptanz der gesch\u00e4tzten glomerul\u00e4ren Filtrationsrate und Albuminurie\/Proteinurie als Surrogatparameter f\u00fcr die Progression bei chronischer Nierenkrankheit. https:\/\/www.dgfn.eu\/stellungnahmen-details\/stellungnahme-zur-akzeptanz-der-geschaetzten-glomerulaeren-filtrationsrate-und-albuminurie-proteinurie-als-surrogatparameter-fuer-die-progression-bei-ckd.html. Zugegriffen: 25. M\u00e4rz 2026"},{"key":"2131_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.111242","volume":"167","author":"R Christensen","year":"2024","unstructured":"Christensen\u00a0R, Ciani\u00a0O, Manyara\u00a0AM et\u00a0al (2024) Surrogate endpoints: a key concept in clinical epidemiology. J\u00a0Clin Epidemiol 167:111242","journal-title":"J Clin Epidemiol"},{"key":"2131_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco\u00a0C, Haapio\u00a0M, House\u00a0AA et\u00a0al (2008) Cardiorenal syndrome. J\u00a0Am Coll Cardiol 52:1527\u20131539","journal-title":"J Am Coll Cardiol"},{"key":"2131_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","volume":"5","author":"M Metra","year":"2012","unstructured":"Metra\u00a0M, Davison\u00a0B, Bettari\u00a0L et\u00a0al (2012) Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5:54\u201362","journal-title":"Circ Heart Fail"},{"key":"2131_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","volume":"72","author":"SS Waikar","year":"2018","unstructured":"Waikar\u00a0SS, Rebholz\u00a0CM, Zheng\u00a0Z et\u00a0al (2018) Biological Variability of Estimated GFR and Albuminuria in CKD. Am J Kidney Dis 72:538\u2013546","journal-title":"Am J Kidney Dis"},{"key":"2131_CR11","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"Ada Professional Practice Committee","year":"2025","unstructured":"Ada Professional Practice Committee (2025) 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care 48:S239\u2013S251","journal-title":"Diabetes Care"},{"key":"2131_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.02870707","volume":"3","author":"AC Baxmann","year":"2008","unstructured":"Baxmann\u00a0AC, Ahmed\u00a0MS, Marques\u00a0NC et\u00a0al (2008) Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3:348\u2013354","journal-title":"Clin J Am Soc Nephrol"},{"key":"2131_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker\u00a0LA, Eneanya\u00a0ND, Coresh\u00a0J et\u00a0al (2021) New Creatinine- and Cystatin C\u2011Based Equations to Estimate GFR without Race. N\u00a0Engl J Med 385:1737\u20131749","journal-title":"N Engl J Med"},{"key":"2131_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.7326\/L21-0248","volume":"174","author":"H Pottel","year":"2021","unstructured":"Pottel\u00a0H, Delanaye\u00a0P (2021) Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 174:1038","journal-title":"Ann Intern Med"},{"key":"2131_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker\u00a0LA, Collier\u00a0W, Greene\u00a0T et\u00a0al (2023) A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med 29:1867\u20131876","journal-title":"Nat Med"},{"key":"2131_CR16","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1093\/eurheartj\/ehaf643","volume":"46","author":"BL Neuen","year":"2025","unstructured":"Neuen\u00a0BL, Vaduganathan\u00a0M (2025) Glomerular filtration rate slope in heart failure: ready for prime time? Eur Heart\u00a0J 46:4594\u20134596","journal-title":"Eur Heart J"},{"key":"2131_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et\u00a0al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"2131_CR18","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh\u00a0J, Turin\u00a0TC, Matsushita\u00a0K et\u00a0al (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama 311:2518\u20132531","journal-title":"Jama"},{"key":"2131_CR19","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1093\/eurheartj\/ehaf457","volume":"46","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi\u00a0M, Bayes-Genis\u00a0A, Duarte\u00a0K et\u00a0al (2025) Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. Eur Heart\u00a0J 46:4583\u20134593","journal-title":"Eur Heart J"},{"key":"2131_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","volume":"26","author":"LS Dalrymple","year":"2011","unstructured":"Dalrymple\u00a0LS, Katz\u00a0R, Kestenbaum\u00a0B et\u00a0al (2011) Chronic kidney disease and the risk of end-stage renal disease versus death. J\u00a0Gen Intern Med 26:379\u2013385","journal-title":"J Gen Intern Med"},{"key":"2131_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.02.027","volume":"13","author":"DZ Anjum","year":"2025","unstructured":"Anjum\u00a0DZ, Elmegaard\u00a0M, Garred\u00a0CH et\u00a0al (2025) Prognosis After \u3009\u202f50\u202f% Decline in eGFR in Heart Failure Patients: A\u00a0Nationwide Real-World Study. JACC Heart Fail 13:102481","journal-title":"JACC Heart Fail"},{"key":"2131_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","volume":"106","author":"HL Hillege","year":"2002","unstructured":"Hillege\u00a0HL, Fidler\u00a0V, Diercks\u00a0GF et\u00a0al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777\u20131782","journal-title":"Circulation"},{"key":"2131_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","volume":"32","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink\u00a0HJL, Collier\u00a0WH, Chaudhari\u00a0J et\u00a0al (2026) A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med 32:281\u2013287","journal-title":"Nat Med"},{"key":"2131_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker\u00a0TA, Wiviott\u00a0SD, Raz\u00a0I et\u00a0al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339","journal-title":"Lancet"},{"key":"2131_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey\u00a0AS, Inker\u00a0LA, Matsushita\u00a0K et\u00a0al (2014) GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64:821\u2013835","journal-title":"Am J Kidney Dis"},{"key":"2131_CR26","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1056\/NEJMra2201153","volume":"386","author":"AS Levey","year":"2022","unstructured":"Levey\u00a0AS, Grams\u00a0ME, Inker\u00a0LA (2022) Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. N\u00a0Engl J Med 386:2120\u20132128","journal-title":"N Engl J Med"},{"key":"2131_CR27","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1111\/dom.15817","volume":"26","author":"A Oulhaj","year":"2024","unstructured":"Oulhaj\u00a0A, Aziz\u00a0F, Suliman\u00a0A et\u00a0al (2024) Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial. Diabetes Obes Metab 26:4602\u20134612","journal-title":"Diabetes Obes Metab"},{"key":"2131_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams\u00a0ME, Coresh\u00a0J, Matsushita\u00a0K et\u00a0al (2023) Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. Jama 330:1266\u20131277","journal-title":"Jama"},{"key":"2131_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","volume":"151","author":"SE Claudel","year":"2025","unstructured":"Claudel\u00a0SE, Verma\u00a0A (2025) Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation 151:716\u2013732","journal-title":"Circulation"},{"key":"2131_CR30","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/sim.8282","volume":"38","author":"E Vonesh","year":"2019","unstructured":"Vonesh\u00a0E, Tighiouart\u00a0H, Ying\u00a0J et\u00a0al (2019) Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med 38:4218\u20134239","journal-title":"Stat Med"},{"key":"2131_CR31","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1681\/ASN.2019010009","volume":"30","author":"T Greene","year":"2019","unstructured":"Greene\u00a0T, Ying\u00a0J, Vonesh\u00a0EF et\u00a0al (2019) Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. J\u00a0Am Soc Nephrol 30:1756\u20131769","journal-title":"J Am Soc Nephrol"},{"key":"2131_CR32","unstructured":"Institut F\u00fcr Qualit\u00e4t Und Wirtschaftlichkeit Im Gesundheitswesen (2025) Allgemeine Methoden, Version 8.0. https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_v8-0.pdf. Zugegriffen: 25. M\u00e4rz 2026"},{"key":"2131_CR33","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker\u00a0LA, Heerspink\u00a0HJL, Tighiouart\u00a0H et\u00a0al (2019) GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J\u00a0Am Soc Nephrol 30:1735\u20131745","journal-title":"J Am Soc Nephrol"},{"key":"2131_CR34","unstructured":"Us Food and Drug Administration (2025) Table of surrogate endpoints that were the basis of drug approval or licensure. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Zugegriffen: 25. M\u00e4rz 2026"},{"key":"2131_CR35","unstructured":"European Medicines Agency (2023) Qualification opinion for GFR slope as a\u00a0Surrogate Endpoint in RCT for CKD. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-qualification-opinion-gfr-slope-surrogate-endpoint-rct-ckd_en.pdf. Zugegriffen: 25. M\u00e4rz 2026"},{"key":"2131_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103465","volume":"88","author":"RS Taylor","year":"2025","unstructured":"Taylor\u00a0RS, Heerspink\u00a0HJL, Buyse\u00a0M et\u00a0al (2025) Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease. EClinicalMedicine 88:103465","journal-title":"EClinicalMedicine"},{"key":"2131_CR37","unstructured":"Gemeinsamer Bundesausschuss (2025) Verfahrensordnung des Gemeinsamen Bundesausschusses. https:\/\/www.g-ba.de\/downloads\/62-492-4060\/VerfO_2025-09-18_iK_2026-02-20.pdf. Zugegriffen: 25. M\u00e4rz 2026"},{"key":"2131_CR38","unstructured":"Coordination Group on Health Technology Assessment (2024) Guidance on outcomes for joint clinical assessments. https:\/\/health.ec.europa.eu\/document\/download\/a70a62c7-325c-401e-ba42-66174b656ab8_en?filename=hta_outcomes_jca_guidance_en.pdf. Zugegriffen: 25. M\u00e4rz 2026"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02131-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:53:23Z","timestamp":1784789603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02131-3"}},"subtitle":["Estimated glomerular filtration und Albuminurie im klinischen Alltag und in Studien","Estimated glomerular filtration rate and albuminuria in clinical practice and in studies"],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02131-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.\u00a0Ebert: Vortrags\u2011\/Beraterhonorare: Abbott, AstraZeneca\/Santis, Bayer Vital GmbH\/Bayer AG, Boehringer Ingelheim, Fresenius Medical Care Deutschland\/Renal Research Institute, New York, NY, USA, Lilly, Novo Nordisk, Sanofi; Forschungsunterst\u00fctzung: AstraZeneca, Bayer, Lilly, Otsuka Pharma. M.\u00a0Guthoff: Forschungsunterst\u00fctzung: Chiesi; Honorare: Alexion, Astellas, AstraZeneca, Bayer, Boehringer, Chiesi, Lilly, Novartis, Sanofi; Reiseuntest\u00fctzung: Alexion, Boehringer Ingelheim, Chiesi, Lilly. U.\u00a0Kintscher: Vortrags\u2011\/Beraterhonorare: Amarin, Apontis, Astra Zeneca, Bayer, Novartis, Ovivia, Sanofi, Servier. K.\u00a0Marx-Sch\u00fctt: Vortragst\u00e4tigkeit: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Novartis; Beratungst\u00e4tigkeit: Amgen, Boehringer Ingelheim, AstraZeneca, Novo Nordisk. J.\u00a0Galle: Vortrags-\/Beraterhonorare von AstraZeneca, Bayer, Boehringer Ingelheim. C.\u00a0Wanner gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}